Last 36 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -7.43 | — | — | — | — | 46.89 | — | — | — | — | — | — | — | — | — | — | — | — | — | 2.73 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 12.44 | 23.71 | 39.83 | 19.39 | 13.93 | 1.35 | 6.90 | 13.13 | 7.28 | 8.89 | 2.81 | 11.55 | 10.46 | 12.82 | 13.32 | 11.15 | 14.32 | 16.85 | 31.21 | 2.15 | 64.60 |
| — | +1650.1% | +477.6% | +47.7% | +91.3% | -84.8% | +145.8% | +13.6% | -30.4% | -30.6% | -78.9% | +3.6% | -26.9% | -23.9% | -57.3% | +418.6% | -77.8% | -66.7% | -37.3% | -95.1% | +1393.3% | |
| P/B Ratio | 4.16 | 8.38 | 5.17 | 4.06 | 3.32 | 1.58 | 1.45 | 2.82 | 2.47 | 2.18 | 2.30 | 3.10 | 2.58 | 2.63 | 2.22 | 2.29 | 2.70 | 2.43 | 2.82 | 3.62 | 4.51 |
| — | +430.6% | +255.3% | +44.1% | +34.3% | -27.7% | -36.8% | -9.2% | -3.9% | -16.8% | +3.7% | +35.7% | -4.8% | +7.9% | -21.3% | -36.9% | -40.0% | -23.1% | -0.5% | +10.4% | +119.7% | |
| P/FCF | — | — | — | — | — | — | — | — | 13.98 | — | — | — | — | — | — | — | — | — | 0.86 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 2.69 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | 90.99 | — | — | — | — | — | — | — | — | — | — | — | — | — | 2.68 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 96.0% | 100.0% | 88.2% | 90.9% | 92.3% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| — | 0.0% | -11.8% | -9.1% | -7.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin | -156.3% | -234.1% | -788.2% | -345.5% | -546.2% | -5.0% | -435.7% | -396.2% | -218.8% | -271.8% | -11.0% | -293.5% | -250.0% | -286.2% | -344.0% | -221.2% | -212.1% | -255.6% | -372.2% | 79.3% | -825.9% |
| — | -4582.9% | -80.9% | +12.8% | -149.7% | +98.2% | -3848.7% | -35.0% | +12.5% | +5.0% | +96.8% | -32.7% | -17.9% | -12.0% | +7.6% | -378.8% | +74.3% | +68.2% | +51.6% | +114.5% | -34438.5% | |
| Net Margin | -142.9% | -222.0% | -752.9% | -297.0% | -519.2% | -5.0% | -400.0% | -361.5% | -191.7% | -238.5% | -2.8% | -261.3% | -221.9% | -258.6% | -320.0% | -200.4% | -197.0% | -248.1% | -377.8% | 78.8% | -824.2% |
| — | -4339.0% | -88.2% | +17.9% | -170.9% | +97.9% | -14400.1% | -38.4% | +13.6% | +7.8% | +99.1% | -30.4% | -12.6% | -4.2% | +15.3% | -354.3% | +76.1% | +69.1% | +50.8% | +114.4% | -29289.8% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -63.3% | -18.4% | -22.2% | -18.4% | -27.4% | -1.5% | -22.0% | -17.9% | -15.3% | -13.9% | -0.7% | -16.5% | -13.1% | -12.9% | -12.7% | -10.0% | -9.0% | -8.7% | -8.3% | 40.4% | -13.6% |
| — | -1143.4% | -0.5% | -2.6% | -78.8% | +89.3% | -3121.9% | -8.5% | -17.3% | -7.7% | +94.6% | -65.8% | -45.4% | -48.2% | -53.3% | -124.7% | +33.9% | +27.5% | +33.3% | +507.5% | -3730.0% | |
| ROA | -30.8% | -9.5% | -12.0% | -9.3% | -13.2% | -0.7% | -9.7% | -7.8% | -7.5% | -7.5% | -0.3% | -7.1% | -5.9% | -6.1% | -6.2% | -4.9% | -4.5% | -4.4% | -4.3% | 23.0% | -9.0% |
| — | -1221.0% | -23.4% | -18.5% | -74.6% | +90.4% | -2799.6% | -10.4% | -28.1% | -23.7% | +94.6% | -43.9% | -30.1% | -36.7% | -41.9% | -121.4% | +49.5% | +46.4% | +49.0% | +450.9% | -3282.9% | |
| ROIC | -63.2% | -16.7% | -21.0% | -20.6% | -29.6% | -1.5% | -23.0% | -18.9% | -17.3% | -15.5% | -2.7% | -19.8% | -17.6% | -17.8% | -13.8% | -9.5% | -8.8% | -10.8% | -8.5% | 34.4% | -15.7% |
| — | -1023.6% | +8.9% | -8.9% | -71.5% | +90.5% | -744.1% | +4.3% | +2.0% | +12.9% | +80.3% | -107.2% | -100.8% | -65.2% | -62.1% | -127.7% | +44.1% | +41.1% | +50.3% | +394.9% | -3245.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.18 | 0.25 | 0.22 | 0.18 | 0.25 | 0.20 | 0.11 | 0.12 | 0.10 | 0.02 | 0.02 | 0.02 | 0.02 | — | — | 0.18 | 0.17 | 0.16 | 0.14 | 0.14 | 0.09 |
| — | +23.7% | +90.8% | +43.5% | +148.0% | +1046.1% | +626.2% | +419.6% | +493.1% | — | — | -87.0% | -89.9% | — | — | +26.0% | +89.1% | +97.3% | +551.6% | +302.1% | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.43 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.36 | 3.82 | 4.04 | 4.36 | 3.65 | 4.50 | 5.37 | 4.50 | 5.24 | 5.14 | 5.22 | 4.52 | 4.41 | 5.47 | 5.66 | 5.52 | 6.21 | 7.48 | 7.84 | 7.60 | 3.82 |
| — | -15.2% | -24.8% | -3.0% | -30.4% | -12.3% | +3.0% | -0.5% | +19.0% | -6.2% | -7.9% | -18.2% | -29.1% | -26.9% | -27.7% | -27.3% | +62.8% | +30.8% | +23.0% | +25.6% | -22.0% | |
| Quick Ratio | 4.36 | 3.82 | 4.04 | 4.36 | 3.65 | 4.50 | 5.37 | 4.50 | 5.24 | 5.14 | 5.22 | 4.52 | 4.41 | 5.47 | 5.66 | 5.52 | 6.21 | 7.48 | 7.84 | 7.60 | 3.82 |
| — | -15.2% | -24.8% | -3.0% | -30.4% | -12.3% | +3.0% | -0.5% | +19.0% | -6.2% | -7.9% | -18.2% | -29.1% | -26.9% | -27.7% | -27.3% | +62.8% | +30.8% | +23.0% | +25.6% | -22.0% | |
| Interest Coverage | -43.13 | -29.33 | -41.67 | -6.00 | -44.00 | 1.00 | -111.00 | -46.00 | -91.00 | — | -3.00 | — | -68.00 | — | -77.00 | -118.82 | — | -66.00 | — | 1084.32 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 36 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RCUS stock.
Arcus Biosciences, Inc.'s current P/E is -7.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Arcus Biosciences, Inc.'s current operating margin is -156.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Arcus Biosciences, Inc.'s business trajectory between earnings reports.